Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020
25th May 2020 - Clinical Spotlight | Telix Presents the IPAX-1 Study at the American Society of Clinical Oncology (ASCO)
The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
1st May 2020 - Corporate Spotlight | Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe...
Telix Pharmaceuticals enters into Exclusive Licence Agreement with Osaka University
Melbourne (Australia) and Osaka (Japan) – 27 April 2020. Telix announces an exclusive Intellectual Property (IP) licence with Osaka University...
Seneffe Manufacturing Facility – Shareholder Walkthrough
Melbourne (Australia) 28 April 2020 - Telix Pharmaceuticals Limited provides a shareholder walkthrough of it's recently acquired Seneffe manufacturing facility